Literature DB >> 34256823

Potential application of human neural crest-derived nasal turbinate stem cells for the treatment of neuropathology and impaired cognition in models of Alzheimer's disease.

Jung Yeon Lim1, Sang In Park2, Soon A Park3, Jung Ho Jeon4, Ho Yong Jung2, Jung-Min Yon4, Sin-Soo Jeun3, Hyun Kook Lim5, Sung Won Kim6.   

Abstract

BACKGROUND: Stem cell transplantation is a fascinating therapeutic approach for the treatment of many neurodegenerative disorders; however, clinical trials using stem cells have not been as effective as expected based on preclinical studies. The aim of this study is to validate the hypothesis that human neural crest-derived nasal turbinate stem cells (hNTSCs) are a clinically promising therapeutic source of adult stem cells for the treatment of Alzheimer's disease (AD).
METHODS: hNTSCs were evaluated in comparison with human bone marrow-derived mesenchymal stem cells (hBM-MSCs) according to the effect of transplantation on AD pathology, including PET/CT neuroimaging, immune status indicated by microglial numbers and autophagic capacity, neuronal survival, and cognition, in a 5 × FAD transgenic mouse model of AD.
RESULTS: We demonstrated that hNTSCs showed a high proliferative capacity and great neurogenic properties in vitro. Compared with hBM-MSC transplantation, hNTSC transplantation markedly reduced Aβ42 levels and plaque formation in the brains of the 5 × FAD transgenic AD mice on neuroimaging, concomitant with increased survival of hippocampal and cortex neurons. Moreover, hNTSCs strongly modulated immune status by reducing the number of microglia and the expression of the inflammatory cytokine IL-6 and upregulating autophagic capacity at 7 weeks after transplantation in AD models. Notably, compared with transplantation of hBM-MSCs, transplantation of hNTSCs significantly enhanced performance on the Morris water maze, with an increased level of TIMP2, which is necessary for spatial memory in young mice and neurons; this difference could be explained by the high engraftment of hNTSCs after transplantation.
CONCLUSION: The reliable evidence provided by these findings reveals a promising therapeutic effect of hNTSCs and indicates a step forward the clinical application of hNTSCs in patients with AD.
© 2021. The Author(s).

Entities:  

Keywords:  5 × FAD mice; Alzheimer’s disease; Cell transplantation; Neurogenic property; hNTSCs

Year:  2021        PMID: 34256823     DOI: 10.1186/s13287-021-02489-1

Source DB:  PubMed          Journal:  Stem Cell Res Ther        ISSN: 1757-6512            Impact factor:   6.832


  88 in total

1.  From marrow to brain: expression of neuronal phenotypes in adult mice.

Authors:  T R Brazelton; F M Rossi; G I Keshet; H M Blau
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

3.  Opposing roles for endogenous BDNF and NT-3 in regulating cortical dendritic growth.

Authors:  A K McAllister; L C Katz; D C Lo
Journal:  Neuron       Date:  1997-05       Impact factor: 17.173

4.  Expression of δNp73 in hippocampus of APP/PS1 transgenic mice following GFP-BMSCs transplantation.

Authors:  Shi-Rong Wen; Hui-Ping Qi; Ya-Jing Ren; Guo-Jun Liu; Feng-Chao Gong; Hua Zhong; Sheng Bi
Journal:  Neurol Res       Date:  2011-12       Impact factor: 2.448

5.  Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges.

Authors:  S M Mueller; J Glowacki
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

6.  Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep.

Authors:  K W Liechty; T C MacKenzie; A F Shaaban; A Radu; A M Moseley; R Deans; D R Marshak; A W Flake
Journal:  Nat Med       Date:  2000-11       Impact factor: 53.440

7.  Bone marrow-derived mesenchymal stem cells contribute to the reduction of amyloid-β deposits and the improvement of synaptic transmission in a mouse model of pre-dementia Alzheimer's disease.

Authors:  Jae-sung Bae; Hee Kyung Jin; Jong Kil Lee; Jill C Richardson; Janet E Carter
Journal:  Curr Alzheimer Res       Date:  2013-06       Impact factor: 3.498

8.  Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease.

Authors:  Mathew Blurton-Jones; Masashi Kitazawa; Hilda Martinez-Coria; Nicholas A Castello; Franz-Josef Müller; Jeanne F Loring; Tritia R Yamasaki; Wayne W Poon; Kim N Green; Frank M LaFerla
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-24       Impact factor: 11.205

9.  Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques.

Authors:  J-Y Kim; D H Kim; J H Kim; D Lee; H B Jeon; S-J Kwon; S M Kim; Y J Yoo; E H Lee; S J Choi; S W Seo; J I Lee; D L Na; Y S Yang; W Oh; J W Chang
Journal:  Cell Death Differ       Date:  2011-10-21       Impact factor: 15.828

Review 10.  The Regenerative Role of the Fetal and Adult Stem Cell Secretome.

Authors:  Sveva Bollini; Chiara Gentili; Roberta Tasso; Ranieri Cancedda
Journal:  J Clin Med       Date:  2013-12-17       Impact factor: 4.241

View more
  3 in total

1.  High throughput screening of mesenchymal stem cell lines using deep learning.

Authors:  Gyuwon Kim; Jung Ho Jeon; Keonhyeok Park; Sung Won Kim; Do Hyun Kim; Seungchul Lee
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

Review 2.  Hippocampal neurogenesis and pro-neurogenic therapies for Alzheimer's disease.

Authors:  Jie Zheng
Journal:  Animal Model Exp Med       Date:  2022-02-06

3.  Protective Effect of Human-Neural-Crest-Derived Nasal Turbinate Stem Cells against Amyloid-β Neurotoxicity through Inhibition of Osteopontin in a Human Cerebral Organoid Model of Alzheimer's Disease.

Authors:  Jung Yeon Lim; Jung Eun Lee; Soon A Park; Sang In Park; Jung-Min Yon; Jeong-Ah Park; Sin-Soo Jeun; Seung Joon Kim; Hong Jun Lee; Sung Won Kim; Seung Ho Yang
Journal:  Cells       Date:  2022-03-18       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.